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ABSTRACT
Recent studies suggest that the RANK/RANKL system impacts muscle function and/or mass. In the pivotal placebo-controlled fracture
trial of the RANKL inhibitor denosumab in women with postmenopausal osteoporosis, treatment was associated with a lower inci-
dence of non-fracture-related falls (p = 0.02). This ad hoc exploratory analysis pooled data from five placebo-controlled trials of deno-
sumab to determine consistency across trials, if any, of the reduction of fall incidence. The analysis included trials in women with
postmenopausal osteoporosis and low bonemass, menwith osteoporosis, women receiving adjuvant aromatase inhibitors for breast
cancer, and men receiving androgen deprivation therapy for prostate cancer. The analysis was stratified by trial, and only included
data from the placebo-controlled period of each trial. A time-to-event analysis of first fall and exposure-adjusted subject incidence
rates of falls were analyzed. Falls were reported and captured as adverse events. The analysis comprised 10,036 individuals; 5030
received denosumab 60 mg subcutaneously once every 6 months for 12 to 36 months and 5006 received placebo. Kaplan–Meier
estimates showed an occurrence of falls in 6.5% of subjects in the placebo group compared with 5.2% of subjects in the denosumab
group (hazard ratio = 0.79; 95% confidence interval 0.66–0.93; p = 0.0061). Heterogeneity in study designs did not permit overall
assessment of association with fracture outcomes. In conclusion, denosumabmay reduce the risk of falls in addition to its established
fracture risk reduction by reducing bone resorption and increasing bone mass. These observations require further exploration and
confirmation in studies with muscle function or falls as the primary outcome. © 2020 The Authors. Journal of Bone and Mineral
Research published by American Society for Bone and Mineral Research..
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Introduction
A common cause of fracture in osteoporosis subjects is afall from a standing height or less; 90% of hip fractures
result from a fall.(1) Therefore, falls risk reduction is an impor-
tant component of primary and secondary fragility
fracture prevention strategies, usually delivered via multidisci-
plinary approaches.(2–5) Such approaches include falls risk
assessment, exercises, medication review (that includes an
assessment of any association with falls for each medication
type being administered, as well as dose reductions or switch-
ing to alternatives that may be less likely to result in falls, if
applicable), and vitamin D supplementation (with or without
calcium).(6–9) This multifaceted approach to falls risk reduction
is often provided in parallel with bone-targeted therapies to
further reduce fracture risk, as it has been assumed that
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osteoporosis drugs, per se, are unlikely to also impact muscle
function or falls risk.
Denosumab is a fully humanmonoclonal antibody to receptor
activator of NF-κB ligand (RANKL).(10) The clearance of RANKL by
denosumab prevents binding to its receptor RANK, inhibiting the
development, function, and survival of osteoclasts.(11) The RANK/
RANKL pathway has also recently been implicated in a role in
muscle strength in a muscular dystrophy murine model.(12,13) In
addition, denosumab treatment has been shown to reverse an
impairment of muscle function and reduction in muscle mass
observed in mice overexpressing RANKL.(14) Of note, a single
case of a woman with facioscapulohumeral muscular dystrophy
with osteoporosis who was administered denosumab andwithin
24 hours showed transient increased grip strength and reduced
dystrophic symptoms indicates that theremay be a role of RANK/
RANKL in the management of this disease.(15) Furthermore, a
recent review presented evidence indicating that RANKL inhibi-
tion with denosumab may benefit patients with Duchenne mus-
cular dystrophy.(16) Preliminary data also support a positive
impact of denosumab on muscle function in women with osteo-
porosis.(14) These studies prompted us to revisit the observation,
largely ignored at the time of study completion, of a significantly
lower incidence of falls in the denosumab arm of the pivotal
Fracture Reduction Evaluation of Denosumab in Osteoporosis
Every 6 Months (FREEDOM) trial.
In this large, placebo-controlled trial in postmenopausal
womenwith osteoporosis, 4.5% of the women receiving denosu-
mab during the 3-year study reported falls as adverse events
(AEs) compared with 5.7% of women in the placebo group
(log-rank p = 0.02).(10) Notably, this observation excluded falls
associated with fracture to try to minimize recall and reporting
bias. To further test the hypothesis that denosumab could mod-
ify falls risk, we undertook an exploratory pooled analysis of all
placebo-controlled trials of denosumab in the treatment of
bone loss.
Materials and Methods
Study design
The analysis comprised data from five placebo-controlled trials
that contributed to the FDA approval of denosumab for use in
bone loss indications. The subjects included postmenopausal
women with osteoporosis (FREEDOM, trial 1), postmenopausal
women with low bone mass (trial 2), men with osteoporosis (trial
3), women with nonmetastatic breast cancer receiving adjuvant
aromatase inhibitors (trial 4), and men with nonmetastatic pros-
tate cancer receiving androgen deprivation therapy (trial
5).(10,17–20) The baseline characteristics of the subjects are shown
(Table 1), and the eligibility criteria of each trial are summarized
(Table 2).
In each study, subjects were randomly assigned to receive
denosumab 60 mg or placebo by subcutaneous injection every
6 months. Calcium and vitamin D supplementation varied
between the trials but was applied equally to the denosumab
and placebo groups; for example, in trials 1 and 2, subjects
received a daily supplement containing at least 1000 mg of cal-
cium, with concomitant vitamin D dosing determined by the
baseline 25-hydroxyvitamin D level.(10,17) None of the studies
included specific advice about exercise or falls prevention.
A fall was defined as a sudden, unintentional coming to rest
on the ground, floor, or other lower level, regardless of whether
an injury had occurred as a result. Subjects were interviewed by
study staff at clinic visits where the number and associated fea-
tures of reported falls were recorded on an AE questionnaire.
Preferred terms were coded using MedDRA (MedDRA, McLean,
VA, USA) version 9.0 for trials 2 and 4, version 11.0 for trials
1 and 5, and version 14.0 for trial 3.
Statistical analysis
The Cox proportional hazards model was used to estimate the
hazard ratio (HR) for incident falls during denosumab treatment
relative to placebo as the reference group using both individual
study data and pooled data. Interactions between treatment effi-
cacy and baseline age were examined using age as a continuous
variable, and as distinct age groups (<75 years and ≥75 years).
The stratification at age 75 years was selected to mirror the pre-
specified subgroup analyses within the FREEDOM trial.(10) Inter-
actions of treatment and falls reduction with a history of
nonvertebral fracture and prevalent vertebral fracture were also
explored in the Cox proportional hazards models. The following
baseline covariates, commonly considered to be associated with
nonvertebral fracture risk, were added to the Cox models (with
Table 1. Description of the Double-blind Denosumab Versus Placebo-controlled Studies Included in the Present Analysis
Trial Study population
No. of subjects
(placebo/
denosumab)
Age (years) (placebo/
denosumab),
mean (SD)
All adverse events
(placebo/denosumab),
n (%)
Denosumab
exposure,
months Reference
Osteoporosis
1 Postmenopausal osteoporosis 3876/3886 72.3 (5.2)/72.3 (5.2) 3607 (93.1)/3605 (92.8) 36 (10)
2 Postmenopausal women with
low bone mass
165/164 58.9 (7.5)/59.8 (7.4) 157 (95.2)/156 (95.1) 24 (17)
3 Men with osteoporosis 120/120 65.1 (9.2)/65.0 (10.2) 87 (73)/87 (73) 12 (18)
Cancer treatment-induced bone loss (CTIBL)
4 Women with aromatase
inhibitor therapy for breast
cancer
120/129 59.7 (9.7)/59.2 (8.9) 108 (90)/117 (90.7) 24 (19)
5 Men with
androgen-deprivation
therapy for prostate cancer
725/731 75.5 (7.1)/75.3 (7.0) 627 (86.5)/638 (87.3) 36 (20)
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Table 2. Summary of Inclusion and Exclusion Criteria for Each Trial
Trial Inclusion Exclusion
Clinicaltrials.
gov
identifiers
1(10) • Postmenopausal women
• Aged 60–90 years
• BMD T-score at lumbar spine or hip less than −2.5
• Had conditions that influence bone metabolism
• Had taken oral bisphosphonates for more than 3 years
 If less than 3 years, they were eligible after
12 months without treatment
• Had used intravenous bisphosphonates, fluoride, or
strontium for osteoporosis within the past 5 years
• Had used PTH or its derivatives, corticosteroids,
systemic hormone-replacement therapy, selective
estrogen-receptor modulators, or tibolone, calcitonin,
or calcitriol within 6 weeks
• BMD T-score at lumbar spine or hip less than −4.0 or
any severe (or more than two moderate) prevalent
vertebral fractures
NCT00089791
2(17) • Ambulatory postmenopausal women
• BMD T-score at lumbar spine between −1.0 and −2.5
• Not receiving medication that affected bone
metabolism (other than calcium and vitamin D
supplements)
• Free from any underlying condition (other than low
BMD) that might have resulted in abnormal bone
metabolism
• Had no history of a fracture after the age of 25 years
• Had received oral bisphosphonates for 3 ormore years,
cumulatively
 Those who had taken oral bisphosphonates for less
than 3 months were eligible
 Those who had taken oral bisphosphonates for
longer than 3 months but less than 3 years
cumulatively were eligible after a 12-month
washout period
• Had received fluoride or strontium ranelate within
5 years
• Had received PTH or PTH derivatives, steroids,
hormone-replacement therapy, selective estrogen
receptor modulators, tibolone, calcitonin, or calcitriol
within 6 weeks
NCT00091793
3(18) • Ambulatory men
• Aged 30–85 years
• BMD T-score at lumbar spine or femoral neck
between −2.0 and −3.5 or between −1.0 and −3.5
with a prior major osteoporotic fracture and had at
least two lumbar vertebrae, one hip, and one forearm
evaluable by DXA
• Severe or >1 moderate vertebral fracture (using a
semiquantitative grading scale)
• Any vertebral fracture or clinical fracture diagnosed
within 6 months before screening
• Diseases that affect bone metabolism
• Vitamin D deficiency
• Had received bisphosphonate treatment for 3 months
or more cumulatively in the past 2 years, for 1 month
or more in the past year, or at any time during the
3-month period before randomization
• Using anabolic steroids or testosterone,
glucocorticoids, calcitonin, calcitriol, or vitamin D
derivatives and other bone-active drugs in a 3-month
period before screening
• A derived glomerular filtration rate
<30 mL/min/1.73 m2
NCT00980174
4(19) • Women
• Aged ≥ 18 years
• Early-stage histologically or cytologically confirmed
breast cancer that was hormone receptor–positive
• Undergoing adjuvant aromatase inhibitor therapy
• Completed treatment with surgery and/or radiation
and chemotherapy ≥4 weeks
• BMD T-score between −1.0 and −2.5
• Serum 25-hydroxyvitamin D levels
• ≥12 ng/mL
• Prior vertebral fracture
• Current use of bisphosphonates
• Use of any antineoplastic therapy apart from
aromatase inhibitors
NCT00089661
5(20) • Men who had histologically confirmed prostate
cancer
• Concurrent receipt of antineoplastic therapy or
radiotherapy
NCT00089674
(Continues)
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and without the interaction term) to explore the robustness of
the unadjusted HRs including history of nonvertebral fracture,
total hip BMD T-score, and geographic region. A different set of
adjusted Cox models were fitted using the following covariates
in the pooled data using treatment group, baseline age (as a con-
tinuous variable), history of nonvertebral fracture, total hip BMD
T-score, and geographic region. All Cox models fitted with the
pooled data were stratified by study to account for population
differences across trials.
In the main analysis, all falls were included in the outcome,
regardless of whether a fracture occurred on the same day; all
analyses were then repeated for falls excluding those reports
that contained a fracture event on the same day. Finally, a sensi-
tivity analysis was carried out using time to the first fall, or non-
vertebral fracture, as the composite outcome, given the
assumption that nonvertebral fractures usually occur as the
result of a fall. All aforementioned analyses were repeated using
the time to the first fall/nonvertebral fracture outcome. Signifi-
cance level was set at alpha = 0.05 for all analyses. All statistical
analyses were performed using SAS version 9.4 (SAS Institute
Inc., Cary, NC, USA).
Qualified researchers may request data from Amgen clinical
studies. Complete details are available at the following: http://
www.amgen.com/datasharing.
Results
The analysis population comprised a total of 10,036 subjects,
16.9% of whom were men. The baseline characteristics of the
pooled subjects in the denosumab and placebo arms from the
five trials are shown (Table 3). The mean age was approximately
72 years, and just under half had sustained a prior fracture. At
baseline, 6682 subjects were aged <75 years (5856 women,
826men), and 3354 subjects were aged ≥75 years (2484 women,
870 men). Overall, the baseline characteristics were similar in
both groups, with median vitamin D values being around
21 ng/mL (53 nmol/L) in all subjects.
Median (Q1, Q3) duration of follow-up in the pooled denosu-
mab group was 36.0 (35.2, 36.3) months versus 35.9 (31.7, 36.2) in
the placebo group. The number of subjects reporting at least one
fall was 5.8% in the pooled placebo group (289 falls in 5006 sub-
jects) compared with 4.6% in the pooled denosumab group
(231 falls in 5030 subjects) (Fig. 1). Of the total 520 incident falls,
40 (7.7%) were serious AEs (SAEs). The exposure-adjusted inci-
dence rate of falls (calculated as the number of subjects who
experienced the event divided by the sum of subject exposure
time in years) was 2.3 in the pooled placebo group compared
with 1.8 in the pooled denosumab group, for a rate ratio (95%
confidence interval [CI]) of 0.77 (0.66, 0.90). The exposure-
adjusted incidence rate of falls excluding fracture was 2.0 in
the pooled placebo group compared with 1.5 in the pooled
denosumab group, for a rate ratio (95% CI) of 0.77 (0.65, 0.91).
In each of the studies, the proportion of fallers was either sim-
ilar or, more commonly, lower in the denosumab arm compared
with the placebo arm. Hazard ratios, estimated by Cox regres-
sion, ranged from 0.16 (95% CI 0.02–1.37) to 0.99 (95% CI
Table 2. Continued
Trial Inclusion Exclusion
Clinicaltrials.
gov
identifiers
• Receiving androgen-deprivation therapy with an
expected duration of such treatment for 12 or more
months
• Aged 70 years or older or younger than 70 years but
had either a low BMD (T-score less than −1.0) at
baseline or a history of an osteoporotic fracture
• Eastern Cooperative Oncology Group performance
status score of 2 or less
• PSA level of more than 5 ng permilliliter after receiving
androgen-deprivation therapy for more than 1 month
• Current use of oral bisphosphonates or previous
exposure to oral bisphosphonates for 3 or more years
or intravenous bisphosphonates within 5 years
 Those who had taken oral bisphosphonates for
longer than 3 months but less than 3 years
cumulatively were eligible if they had been free of
oral bisphosphonates for ≥1 year
• BMD T-score less than −4.0
• Currently receiving treatment for osteoporosis
BMD = bone mineral density; DXA = dual-energy x-ray absorptiometry; PSA = prostate-specific antigen; PTH = parathyroid hormone.
Table 3. Pooled Subject Characteristics
Baseline characteristics
Placebo Denosumab
n = 5006 n = 5030
Age (years), mean (SD) 71.9 (6.9) 71.8 (6.8)
Women, n (%) 4161 (83.1) 4179 (83.1)
Years since menopause,
mean (SD)
23.3 (8.3)* 23.3 (8.3)*
Any historical fracture,
n (%)
2446 (48.9) 2438 (48.5)
Any historical
nonvertebral fracture,
n (%)
1765 (35.3) 1732 (34.4)
Prevalent vertebral
fracture, n (%)
1116 (22.3) 1125 (22.4)
Baseline BMD T-score,
mean (SD)
Lumbar spine −2.38 (1.29) −2.35 (1.31)
Total hip −1.70 (0.93) −1.68 (0.92)
Serum CTX (ng/mL),
median (Q1, Q3)
0.54 (0.38, 0.73) 0.54 (0.38, 0.73)
Serum 25-OH vitamin D
(ng/mL), median (Q1,
Q3)
21.1 (16.4, 28.3) 21.0 (16.4, 28.5)
*These results exclude the two studies in men.
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0.14–7.04) with an overall effect of a 21% reduction in fallers
(HR = 0.79, 95% CI 0.66–0.93) (Fig. 1).
The estimated Kaplan–Meier incidence of falls was 6.5% of
subjects in the pooled placebo group compared with 5.2% in
the pooled denosumab group, with an HR of 0.79 (95% CI
0.66–0.93; p = 0.0061). The time to first fall in subjects random-
ized to denosumab compared with those receiving placebo is
shown in Fig. 2.
Importantly, the pooled HR estimate for falls was similar after
adjusting for baseline age (as a continuous variable), total hip
BMD T-score, history of nonvertebral fracture, and geographic
region. In addition, there was no significant interaction with a
baseline history of nonvertebral fracture or prevalent vertebral
fracture. There was, however, a significant interaction between
denosumab therapy and age on falls risk when age was consid-
ered as a continuous variable (p = 0.045) (Supplemental Fig. S1).
A greater reduction in falls was observed with denosumab treat-
ment in subjects aged <75 years versus subjects ≥75 years
(interaction p value = 0.012). Thus, denosumab treatment was
associated with a 35% reduction in fall risk in subjects <75 years
(HR = 0.65, 95% CI 0.52–0.82) but no apparent reduction in sub-
jects ≥75 years (HR = 1.01, 95% CI 0.78–1.31), though a possible
early effect on falls risk was suggested (Fig. 3). In contrast to
age, no significant interaction was found between the reduction
in falls risk and sex (p = 0.96).
Discussion
Using pooled data from five placebo-controlled studies of deno-
sumab, this exploratory analysis suggests that 6-monthly subcu-
taneous denosumab can reduce the number of fallers by
Fig. 1. Forest plot of time to first occurrence of fall according to individual studies and the overall. N = number of subjects who received at least one dose
of investigational product in trial 1 (placebo-controlled 36 months), trial 2 (placebo-controlled only first 24 months), trial 3 (placebo-controlled only first
12 months), trial 4 (placebo-controlled only first 24 months), trial 5 (placebo-controlled only first 36 months). Hazard ratio and 95% CIs are based on Cox
proportional hazards model; overall estimates are based on Cox proportional hazards model stratified by study. Q6M = every 6 months.
Fig. 2. Kaplan–Meier plot of time to first fall by treatment group from pooled data of five placebo-controlled studies. Numbers at risk for each group for
the different time points are shown. Q6M = every 6 months.
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approximately 20%. Most fractures, including virtually all nonver-
tebral fractures, occur in the setting of a fall-related injury, lead-
ing to the use of two parallel management strategies, namely
to reduce falls risk and improve bone strength. The possibility
that treatments targeted to one strategy might impact on the
other is not new; for example, it has long been assumed that
the effects of vitamin D supplementation might have beneficial
effects on both, though the effects are modest.(9,21) However,
the observation that therapies developed as specific bone-
targeted agents, such as denosumab, might also impact muscle
function and falls risk is a novel development.
The apparent reduction in falls risk observed here is of clinical
importance and is similar in magnitude to that achieved by inter-
ventions targeted directly at falls risk. For example, in a recent
systematic review, multifactorial interventions, which varied sub-
stantially across the studies but included exercise, nutritional
therapy, knowledge, medication management, urinary inconti-
nence management, environmental modifications, and referral
to physical or occupational therapy or other specialties, were
found to reduce the incidence of falls in older adults by an iden-
tical amount (21%; incidence rate ratio [IRR] = 0.79, 95% CI
0.68–0.91) to that observed with denosumab.(3) Interventions
based on exercise have also shown a similar reduction (19%;
IRR = 0.81, 95% CI 0.73–0.90) in injurious falls, though not an
overall reduction in all falls (IRR = 0.87, 95% CI 0.75–1.00).(3)
Exercise-based trials have also usually demonstrated high drop-
out rates, despite relatively short durations and follow-up
periods.(22) Compliance with exercise is also not high, with one
analysis reporting that approximately 22% of subjects were non-
compliant and 41% were partially compliant.(23) Vitamin D with-
out calcium supplementation also shows inconclusive results
from several meta-analyses, largely depending on study popula-
tions. Vitamin D at doses of 200 to 1000 IU/d is associated with a
14% falls reduction (relative risk = 0.86, 95% CI 0.79–0.93) for
older adults aged 60 years or older.(8) In another analysis, vitamin
D at doses of 700 to 1000 IU/d reduced falls risk by 19%
(RR = 0.81, 95% CI 0.71–0.92), whereas a lower dose was
ineffective (RR = 1.10, 95% CI 0.89–1.35).(24) However, a recent
systematic review concluded that vitamin D supplementation
(either with or without calcium) showed mixed results in adults
without vitamin D deficiency or osteoporosis of increased,
decreased, or no difference in falls prevention between control
and intervention groups; however, another recent study showed
that vitamin D supplementation is beneficial in institutionalized
persons and in people with vitamin D deficiency at risk for frac-
tures (ie, with a history of falls or with mobility, gait, or balance
problems).(3,25)
The question arises as to what potential mechanism might
underlie our observations. While much early focus on the impact
of inhibition of RANK/RANKL centered on its key role as a final
mediator in the regulation of bone remodeling, it is well estab-
lished that the pathway also exists in other tissues, including
skeletal muscle.(11,26) Indeed, there has been interest shown in
the potential benefits of RANKL inhibition inmuscular dystrophy.
For example, a systemic injection of osteoprotegerin (OPG), a sol-
uble decoy receptor of RANKL, has been shown to restoremuscle
force and improve muscle histology in dystrophic mdx mice,
which have the same dystrophinmutation as human patients.(27)
The same research group found that muscle RANK is a key regu-
lator for calcium ion storage and sarco/endoplasmic reticulum
Ca2+ATPase (SERCA) activity and function of fast-twitch skeletal
muscles.(28) That pathways in addition to RANKL/RANK may play
an important role in muscular dystrophy was recently suggested
by the observation that full-length OPG-Fc was superior to anti-
RANKL in alleviating muscular dystrophy in the mouse model.(12)
Outside the setting ofmuscular dystrophy, RANKL overexpres-
sion in a transgenic mouse model has been shown to induce
lower maximal speed and force of the limb, with significant
reductions in the lower gastrocnemius and soleus muscle mass,
as well as severe osteoporosis.(29) Treatment with OPG-Fc was
associated with reversal of the functional findings, with an
increase in the maximal speed and force of the limb. In a more
recent study in the same mouse model, denosumab has also
been shown to increase limb force and gastrocnemius muscle
Fig. 3. Kaplan–Meier plot of time to first fall by treatment group and age group stratified at the age of 75 years from pooled data of five placebo-
controlled studies. Numbers at risk for each group for the different time points are shown. Q6M = every 6 months.
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mass (+34.7% and +9.8% versus vehicle, respectively, p < 0.05).
Importantly, in a small cohort of postmenopausal women receiv-
ing denosumab, the same research group showed that treat-
ment was associated with improved lumbar spine BMD,
appendicular lean mass, and handgrip over 3 years when com-
pared with controls.(14) It should be noted, however, that in a
larger cohort of 441 women studied within the placebo-
controlled FREEDOM study, denosumab was not found to have
any significant impact on total lean body mass.(30) A further pos-
sibility is that of cross-talk between bone and muscle, whereby
osteokines released from bone during bone resorption may
induce muscle loss and/or weakness.(31,32) If applicable, then
other inhibitors of bone resorption might also impact muscle
function and falls risk. Several reports using the combination of
vitamin D and alendronate show improved muscle
function.(33–35) Whether such effects occur in humans in the set-
ting of osteoporosis remain to be determined.
Our analysis also found a significant interaction between
denosumab, falls risk, and subject age, in that the protective
effect of denosumab on falls risk seemed to be decreased at
older ages. There was a higher proportion of men in the older
age group (≥75 years) than the younger age group (25.9% versus
12.4%, respectively), raising the possibility of a sex difference in
the effect of denosumab; this was countered by the finding of
no interaction between sex and efficacy (p = 0.96). A more likely
explanation is that, while low muscle mass and impaired muscle
function are undoubtedly of importance in falls risk in older peo-
ple, multimorbidity, frailty, and other deficits are also likely to
contribute, eg, polypharmacy, orthostatic hypotension, vestibu-
lar disorders, cataracts, and macular degeneration.(36–38)
Several limitations of the present analysis need to be noted.
Importantly, this is a post hoc study, and although conducted
in the setting of randomized controlled clinical trials, none were
designed to prospectively or retrospectively collect and validate
falls data. Fall events were derived from AE and SAE reports;
although the potential impact of treatment on injurious falls
would be of more clinical importance, only 40 (7.7%) of the
reports were SAEs, suggesting an event that required hospital
attendance or admission. This does not imply that the other falls
were injury-free or without impact on quality of life or fear of fall-
ing.(39) Causes of falls were also not collected in the trials, so we
are unable to discriminate falls that might result from muscle
dysfunction from those that relate to other causes discussed
above. None of the studies collected specific falls-related risk fac-
tors at baseline (eg, prior falls, muscle strength, gait speed, and
timed up and go), so no adjustment was possible for such mea-
sures, and it was not possible to examine the effect of denosu-
mab specifically in high fall risk subjects. Adjustment for prior
fracture was undertaken to at least partially account for prior falls
as most fractures would have resulted from a fall-related injury.
Furthermore, the primary analyses were conducted within the
individual studies, and the likelihood of significant imbalance
in event recall or measures of muscle strength or function is
low. Certainly, such measures should be included in future stud-
ies. Prospective measurements of vitamin D levels were not
undertaken during the studies, but as noted above, the impact
of vitamin D on falls risk is uncertain, and the randomized nature
of the studies suggests that differences in uptake of vitamin D
supplementation between trial arms of sufficient magnitude to
mediate the result is highly unlikely.
In addition to the bone turnover and density-mediated
fracture risk reduction in subjects with postmenopausal osteo-
porosis, low bone mass, male osteoporosis, and cancer
treatment-induced bone loss, denosumab may also reduce the
risk of falls in these patients. This observation identifies the need
for further high-quality, appropriately powered and designed
studies to explore the effect of denosumab on muscle mass
and function.
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